Clearmind Medicine (CMND) Depreciation & Amortization (CF) (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Depreciation & Amortization (CF) of $11230.0 for Q2 2026, up 20.77% year-over-year from $9299.0 in Q2 2025, and up 6.27% quarter-over-quarter from $10567.0 in Q1 2026.
Clearmind Medicine (CMND) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Clearmind Medicine's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $11230.0 for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 20.77% year-over-year to $11230.0; the TTM figure through Apr 2026 stood at $41636.0 (down 26.3% YoY), while the FY2025 annual figure was $38415.0, down 1.56% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $11230.0, up from $10567.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $4.3 billion in Q3 2022, with the low at $269.0 in Q3 2024.
- The 5-year median for Depreciation & Amortization (CF) is $9299.0 (2025), against an average of $285.5 million.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) slumped 100.0% in 2023, then surged 3529.0% in 2025.
- Clearmind Medicine's Depreciation & Amortization (CF) stood at $4.3 billion in 2022, then plunged by 100.0% to $29778.0 in 2023, then rose by 26.44% to $37651.0 in 2024, then plunged by 73.24% to $10077.0 in 2025, then rose by 11.44% to $11230.0 in 2026.
- Business Quant data shows CMND's Depreciation & Amortization (CF) at $11230.0 in Q2 2026, $10567.0 in Q1 2026, and $10077.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 11,230.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 11,230.00 |
| Apr 30, 2026 | 11,230.00 |
| Jan 31, 2026 | 10,567.00 |
| Jan 31, 2026 | 10,567.00 |
| Oct 31, 2025 | 10,077.00 |
| Oct 31, 2025 | 10,077.00 |
| Jul 31, 2025 | 9,762.00 |
| Jul 31, 2025 | 9,762.00 |
| Apr 30, 2025 | 9,299.00 |
| Apr 30, 2025 | 9,299.00 |
| Jan 31, 2025 | 9,277.00 |
| Jan 31, 2025 | 9,277.00 |
| Oct 31, 2024 | 37,651.00 |
| Oct 31, 2024 | 37,651.00 |
| Jul 31, 2024 | 269.00 |
| Jul 31, 2024 | 269.00 |
| Apr 30, 2024 | 726.00 |
| Apr 30, 2024 | 726.00 |
| Jan 31, 2024 | 377.00 |
| Jan 31, 2024 | 377.00 |